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Abstract 
Background/Aims: In patients with septic shock, the degree of liver dysfunction is 
correlated with serum levels of soluble intercellular adhesion molecule (sICAM)-1. We 
aimed to assess the usefulness of serum levels of soluble adhesion molecules as 
prognostic factors for acute liver failure (ALF). 
Methods: Serum levels of soluble platelet endothelial cell adhesion molecule 
(sPECAM)-1, sICAM-3, soluble endothelial (sE)-selectin, sICAM-1, soluble 
platelet-selectin, and soluble vascular cell adhesion molecule-1 on admission were 
measured in 37 ALF patients and 34 healthy controls. 
Results: Twenty-two ALF patients (59%) reached to fatal outcomes. Serum levels of 
sPECAM-1, sICAM-3, sE-selectin and sICAM-1 were higher in ALF patients than 
healthy controls. In 37 ALF patients, by the multivariate logistic regression analysis, 
ratio of direct to total bilirubin (per 0.1 increase; odds ratio 0.11, 95% CI 0.01-0.99), 
serum sPECAM-1 level (per 100 ng/ml increase; odds ratio 4.37, 95% CI 1.23-15.5) 
and serum sICAM-1 level (per 100 ng/ml increase; odds ratio 0.49, 95% CI 0.27-0.89) 
were associated with fatal outcomes. Using receiver operating characteristics curve, 
each area under the curve of serum sPECAM-1 and sICMA-1 levels as prognostic 
factors was 0.71 and 0.74, respectively. 
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Conclusion: Serum sPECAM-1 and sICAM-1 levels may be useful for predicting the 
prognosis of ALF. 
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Introduction 
Acute liver failure (ALF) is the clinical manifestation of liver cell death of a 
critical degree with insufficient hepatocellular regeneration and characterized by hepatic 
encephalopathy and coagulopathy [1]. The survival rate without liver transplantation is 
over 60% in patients with acetaminophen-induced ALF and 20-30% in those with 
non-acetaminophen-related ALF [2]. Many of ALF patients rapidly progress to death 
from multiple organ failure (MOF). In order to rescue more ALF patients, it is important 
to accurately predict their prognosis. 
Up to now, elevated serum levels of soluble adhesion molecules such as soluble 
intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 
(sVCAM-1), and soluble endothelial (sE)-selectin have been reported to be associated 
with the development of MOF [3,4]. Furthermore, in acute pancreatitis and severe burn, 
serum levels of sICAM-1 and sVCAM-1 have been shown to reflect the severity of the 
disease and be associated with the prognosis [5,6].  
In patients with sepsis or septic shock, serum sICAM-1 levels have been reported 
to be correlated with serum bilirubin levels [7,8]. Furthermore, in patients with 
alcoholic liver cirrhosis, serum sICAM-1 levels have been shown to be correlated with 
prothrombin activities and serum bilirubin levels and be associated with the prognosis 
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[9]. On the other hand, in an endotoxic shock model, inhibition of adhesion molecule 
such as platelet (P)-selectin and ICAM-1 have been reported to reduce the degree of 
liver injury [10]. Thus, we speculated that serum levels of soluble adhesion molecules 
might be associated with the clinical outcomes of ALF patients.  
This study aimed to investigate whether serum levels of soluble adhesion 
molecules were useful to predict the prognosis of ALF patients. 
 
Methods 
This study was approved by the Institutional Review Board at Okayama 
University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences. 
Patients 
The study-subjects consisted of 37 ALF patients and 34 healthy controls.  
In this study, patients showing prothrombin activities of 40% or less of the 
standardized values due to severe liver damage within 8 weeks of the onset of disease 
symptoms were diagnosed as ALF [11]. Hepatic coma was graded on the standard scale 
of I to IV [12]. However, those who’s computed tomography showed the features of 
chronic liver disease (splenomegaly or varices, collaterals) were excluded. 
Etiology of ALF 
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A diagnosis of hepatitis A and B was made based on the presence of IgM 
anti-hepatitis A virus antibody, and IgM anti-hepatitis B virus core antibody or hepatitis 
B surface antigen, respectively [13]. A diagnosis of autoimmune hepatitis was made 
according to the criteria revised by the International Autoimmune Hepatitis Group in 
1999 [14]. A diagnosis of drug-induced liver injury was made based on the distinctive 
clinical course. A diagnosis of indeterminate liver failure was established when all of 
IgM anti-hepatitis A virus antibody, IgM anti-hepatitis B virus core antibody, hepatitis B 
surface antigen, hepatitis C virus-RNA, anti-nuclear antibody and anti-smooth muscle 
antibody were negative with no obvious cause such as drug, acute fatty liver of 
pregnancy, ischemic hepatitis, Wilson’s disease, malignant infiltration, cytomegalovirus 
infection, Epstein-Barr virus infection and herpes simplex virus infection. 
Measurement of serum level of soluble adhesion molecule 
Serum was collected when each patient admitted to our hospital, and stored at 
-80°C.   
Serum levels of 6 soluble adhesion molecules were measured using the 
FlowCytomix Multiple Analyte Detection System with the Adhesion 6plex (eBioscience, 
San Diego, CA, USA), according to the manufacturer's protocol. This panel consisted of 
soluble platelet endothelial cell adhesion molecule (sPECAM)-1, sICAM-3, sE-selectin, 
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sICAM-1, sP-selectin and sVCAM-1. In brief, the Adhesion 6plex Standard diluted in 
assay buffer and samples were added to a 96 well filter plate. Antibody-coupled beads 
were added to all wells and incubated with phycoerythrin-conjugated second antibodies 
for 2 hours with continuous shaking. The beads were washed twice with assay buffer 
and re-suspended in assay buffer. The reaction mixture was analyzed using the 
MACSQuant Analyzer with MACSQuantify Software v2.2 (Miltenyi Biotec GmbH, 
Bergisch Gladbach, Germany). Each serum level of soluble adhesion molecule was 
automatically calculated by FlowCytomix Pro 2.4 software (eBioscience, San Diego, 
CA, USA) using the appropriate standard curve. 
Statistical Analysis 
SPSS statistical program (release 11.0.1 J, SPSS, Chicago, IL, USA) was used for 
the statistical analysis. 
Dichotomous variables were compared by the χ2-test. Continuous variables were 
expressed as median (range). The Mann–Whitney U test was used to evaluate 
differences in the continuous variables between two groups, and the Kruskal-Wallis test 
was carried out among three groups. Spearman correlation coefficient was used to 
evaluate the consistency in the continuous variables between two groups. To identify 
prognostic factors for fatal outcome (liver transplantation or death), we developed the 
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univariate logistic regression model. The variables, which showed p <0.05 by the 
univariate analysis, were included into the multivariate logistic regression model. The 
prognostic accuracy of each factor which elicited by the logistic regression analyses was 
evaluated based on the area under the curve (AUC) using receiver operating 
characteristics (ROC) curve analysis. P-values <0.05 were considered significant. 
 
Results 
Clinical characteristics 
Table 1 shows clinical characteristics and laboratory data on admission in 37 ALF 
patients. Of 37 ALF patients, 28 were diagnosed with ALF with hepatic coma (≥ grade 
II) and 9 with ALF without hepatic coma (grade 0 or I). All patients underwent culture 
(blood, tracheal aspirate, and urine) and computed tomography (head, chest, and 
abdomen) at the diagnosis of ALF; however, none clinically developed bacterial or 
fungal infection. 
Overall, 15 survived without liver transplantation, 14 received living donor liver 
transplantation, and 8 died without liver transplantation. Thus, 22 patients reached to 
fatal outcomes (liver transplantation or death). 
Serum level of soluble adhesion molecule 
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Table 2 shows serum levels of 6 soluble adhesion molecules on admission in 37 
ALF patients and 34 healthy controls. Serum levels of sPECAM-1, sICAM-3, 
sE-selectin and sICAM-1 in 37 ALF patients were higher than those in 34 healthy 
controls. In 37 ALF patients, 22 patients reaching fatal outcome showed higher serum 
sPECAM-1 levels (P = 0.030) and lower serum sICAM-1 levels (P = 0.014) than 15 
survivors without liver transplantation. On the other hand, there was no difference in 
serum levels of 6 soluble adhesion molecules between 28 ALF patients with hepatic 
coma and 9 ALF patients without hepatic coma (Table 3). Furthermore, in 15 survivors, 
there were no differences in serum levels of sPECAM-1 {577 (495-784) ng/ml versus 
558 (194-898) ng/ml; P = 0.48} and sICAM-1 {1993 (1748-2246} ng/ml versus 1892 
(1264-2737) ng/ml; P = 0.91} between 6 ALF patients with hepatic coma and 9 ALF 
patients without hepatic coma. 
In 28 ALF patients with hepatic coma, 22 patients reaching fatal outcomes 
showed lower serum sICAM-1 levels {1423 (124-2839) ng/ml versus 1993 (1748-2246) 
ng/ml; P = 0.036} than 6 survivors; however there were no differences in serum levels 
of other 5 soluble adhesion molecules between the 2 groups. 
Serum level of soluble adhesion molecule as prognostic factor for ALF 
In the univariate logistic regression model, platelet count, ratio of direct to total 
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bilirubin (D/T ratio), serum sPECAM-1 level and serum sICAM-1 level on admission 
were associated with fatal outcomes in 37 ALF patients. However, the association of 
prothrombin activity on admission with the prognosis was equivocal (Table 4). 
In the multivariate logistic regression analysis, D/T ration (odds ratio 0.11, 95% 
confidence interval 0.01-0.99), serum sPECAM-1 level (odds ratio 4.37, 95% 
confidence interval 1.23-15.5) and serum sICAM-1 level (odds ratio 0.49, 95% 
confidence interval 0.27-0.89) were associated with fatal outcomes in 37 ALF patients 
(Table 5).  
Based on the ROC curves of serum levels of sPECAM-1 and sICAM-1 for 
estimating fatal outcomes in the 37 ALF patients, the AUC was 0.71 (P = 0.007) and 
0.74 (P = 0.005), respectively. On the other hand, the AUC of platelet count, 
prothrombin activity, and D/T ratio was 0.77 (P = 0.014), 0.70 (P = 0.050), and 0.85 (P 
<0.0001), respectively. 
In 37 ALF patients, serum sPECAM-1 level was inversely correlated with 
prothrombin activity (r = -0.52, P = 0.0017). Serum sICAM-1 level was significantly 
correlated with platelet count (r = 0.50, P = 0.0025) and D/T ratio (r = 0.53, P = 0.0015). 
When ALF patients showing serum sPECAM-1 level ≥650 ng/ml on admission 
were estimated to reach fatal outcomes, the sensitivity and specificity were 68% and 
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73%, respectively. On the other hand, when patients showing serum sICAM-1 level 
≤1750 ng/ml on admission were estimated to reach fatal outcomes, the sensitivity and 
specificity were 68% and 73%, respectively. 
 
Discussion 
Recently, the prognosis of ALF patients has been improved due to the advances in 
supportive intensive care: however liver transplantation is the only effective 
intervention for those with fatal outcomes [15]. On the other hand, in Asian countries, 
the donation from deceased donors is severely limited because of various cultural and 
social reasons [16]. Approximately 50% of patients listed for emergency liver 
transplantation have died while awaiting a graft because of the lack of a timely suitable 
donor [17,18]. So, in order to rescue more patients in a setting of the shortage of liver 
grafts, prognostic factors useful to determine the suitable timing for liver transplantation 
are required. 
In ALF, elevated serum levels of pro-inflammatory cytokines such as interleukin 
(IL)-1β, IL-6, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ have been reported 
to be associated with the disease pathogenesis and clinical outcomes [19-22]. These 
pro-inflammatory cytokines promote the secretion of soluble adhesion molecules such 
 12 
as sICAM-1, sVCAM-1 and sE-selectin from the endothelial cells [23-25]. Thus, we 
speculated that some soluble adhesion molecules might be associated with the clinical 
outcomes of ALF. 
In this study, serum levels of sPECAM-1 and sICAM-1 were significantly 
associated with the prognosis of ALF patients. Furthermore, the accuracy of serum 
levels of sPECAM-1 and sICAM-1 for predicting the prognosis of ALF seemed 
approximately equal to platelet count and prothrombin activity, which have been 
reported as important prognostic factors for ALF [26]. On the other hand, although ALF 
patients with hepatic coma has been reported to reach fatal outcomes more frequently 
than those without hepatic coma [11], there were no differences in serum levels of 
sPECAM-1 and sICAM-1 between these 2 groups in this study. So, we consider that 
serum levels of sPECAM-1 and sICAM-1 may be worth investigating as biomarkers for 
predicting the prognosis and determining the suitable timing for liver transplantation in 
ALF patients. 
ICAM-1 is a member of the immunoglobulin-superfamily of cell adhesion 
molecules and expressed on both hematopoietic and non-hematopoietic cells [27]. 
ICAM-1 binds to its main leukocyte ligand, lymphocyte function associated molecule 
(LFA)-1, and plays an important roles in the trans-endothelial migration of leukocytes to 
 13 
sites of inflammation and the activation of T cells [27,28]. On the other hand, sICAM-1, 
which consists of the five extracellular immunoglobulin-domains of the 
membrane-bound ICAM-1 molecule and lacks the transmembrane and cytoplasmic 
domains, inhibits ICAM-1 interaction with LFA-1 and attenuates inflammation [28-30]. 
Furthermore, sICAM-1 has been reported to promote angiogenesis [31]. Angiogenesis 
plays an important role in liver regeneration [32].
 
Thus, insufficient elevation of serum 
sICAM-1 levels in ALF patients may lead to the continuation of intra-hepatic 
inflammation and be associated with the failure of liver regeneration.  
Generally, serum sICAM-1 levels have been reported to be higher in patients with 
inflammatory disorders, especially in those with poor prognosis [3,33,34]. However, 
this study indicated that, in ALF patients, lower serum sICAM-1 levels were associated 
with their fatal outcomes. Part of sICAM-1 has been reported to be secreted from 
hepatocytes stimulated with pro-inflammatory cytokines such as IFN-γ, IL-1β and 
TNF-α [35]. After hepatic resection, serum sICAM-1 levels have been shown to 
decrease [36]. In this study, serum sICAM-1 level was correlated with D/T ratio, which 
reflects hepatic bilirubin conjugation capacity, in ALF patients. Thus, serum sICAM-1 
levels may reflect the grade of hepatic dysfunction in ALF patients. In order to confirm 
these findings, a further study with a larger sample size is required. 
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This study firstly showed the association of serum sPECAM-1 levels with the 
prognosis of ALF patients. PECAM-1 is a member of the immunoglobulin-superfamily 
of cell adhesion molecules and expressed on most cells of the hematopoietic lineage 
including platelets [37]. sPECAM-1 lacks the cytoplasmic and trans-membrane domains. 
In this study, serum sPECAM-1 level was inversely correlated with prothrombin activity. 
In ALF, the intra-hepatic and intra-vascular activation of coagulation, which decreases 
prothrombin activity and platelet count, results in micro-thrombus formation and local 
ischemia and contributes to the progression of the disease [38]. Serum sPECAM-1 
levels have been reported to be associated with the development of ischemic stroke and 
acute coronary syndrome [39,40]. Thus, elevated serum sPECAM-1 levels in ALF 
patients are considered to reflect coagulation activation. 
We consider that, in order to assess the usefulness of serum sPECAM-1 and 
sICAM-1 levels as biomarkers for predicting outcomes of ALF patients, the relation 
between the changes of these levels during the clinical course and the prognosis of ALF 
patients should be assessed, although, in this study, we could not for lack of the serum 
collection after the introduction of treatment in ALF patients. Hereafter, to clarify this 
point is necessary. 
In conclusion, this study indicated that serum levels of sPECAM-1 and sICAM-1 
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on admission were associated with the prognosis of ALF patients. We consider that 
serum levels of sPECAM-1 and sICAM-1 may be worth investigating as biomarkers for 
predicting their outcomes and determining the suitable timing for liver transplantation. 
A further study with a large sample size is required.
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Table 1. Clinical characteristics and labolatory data on admission in 37 patients with 
acute liver failure. 
 Survive Fatal outcome P value 
Patients, n 15 22  
Age, yr 37 (16-71) 38 (27-73) 0.40 
Gender, female (%) 8 (53) 14 (64) 0.39 
Etiology, n (%)    
  Viral hepatitis 8 (53) 9 (41) 0.55 
    Hepatitis A virus 3 0   
    Hepatitis B virus 5 9  
Autoimmune hepatitis 4 (27) 5 (23)  
Drug-induced liver injury 2 (13) 3 (13)  
Indeterminate 1 (7) 5 (23)  
Hepatic coma, n (%)   0.0001 
  0 or I 9 (60) 0 (0)  
  II 5 (33) 16 (73)  
III or IV 1 (7) 6 (27)  
Laboratory data  
 25 
  White blood cell, /mm
3
 7800 (4200-28000) 10165 (2300-25300) 0.27 
  Hemoglobin, g/dl 13.1 (7.3-18.4) 13.2 (8.4-16.4) 0.86 
  Platelet, x10
4
/mm
3
 14.6 (9.0-30.9) 9.1 (2.4-40.3) 0.007 
  Bilirubin, mg/dl 8.9 (3.9-26.0) 11.2 (2.3-32.8) 0.44 
D/T ratio 0.67 (0.57-0.72) 0.52 (0.31-0.75) 0.0003 
AST, IU/l 1036 (215-17340) 497 (41-18360) 0.18 
  ALT, IU/l 2504 (220-7990) 1177 (24-10470) 0.23 
  Creatinine, mg/dl 0.6 (0.4-2.6) 0.7 (0.4-4.8) 0.34 
  Prothrombin activity, % 32 (11-40) 23 (6-40) 0.034 
Prognosis, n (%)    
  Liver transplantation 0 (0) 14 (64)  
  Death without liver transplantation    
 0 (0) 8 (36)  
ALT, alanine aminotransferase; AST, aspartate aminotransaminase; D/T ratio, ratio of 
direct to total bilirubin.  
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Table 2. Serum level of soluble adhesion molecule on admission. 
 Acute liver failure patient   
 Overall Survive Fatal outcome Healthy control P-value 
Patients, n 37 15 22 34  
sPECAM-1, ng/ml 664 (194-2049) 558 (194-898) 850 (313-2049) 338 (171-1072) <0.0001 
sICAM-3, ng/ml 286 (43-1170) 286 (43-674) 273 (51-1170) 88 (8-290) <0.0001 
sE-selectin, ng/ml 422 (140-1162) 440 (140-1098) 360 (169-1162) 108 (35-404) <0.0001 
sICAM-1, ng/ml 1783 (124-2839) 1892 (1264-2737) 1423 (124-2839) 666 (279-1604) <0.0001 
sP-selectin, ng/ml 185 (21-499) 139 (59-499) 192 (21-418) 201 (44-475) 0.33 
sVCAM-1, ng/ml 2468 (719-3898) 2415 (719-3574) 2442 (898-3898) 2208 (1262-3574) 0.84 
Each parameter was compared between 37 patients with acute liver failure and healthy 
controls. E-selectin, endothelial-selectin; ICAM-1, intercellular adhesion molecule-1; 
ICAM-3, intercellular adhesion molecule-3; PECAM-1, platelet endothelial cell 
adhesion molecule-1; P-selectin, platelet-selectin; s, soluble; VCAM-1, vascular cell 
adhesion molecule-1. 
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Table 3. Serum level of soluble adhesion molecule on admission in 37 patients with 
acute liver failure. 
 Hepatic coma grade  
 0 or I II or higher P-value 
Patients, n 9 28  
sPECAM-1, ng/ml 558 (194-898) 742 (313-2049) 0.061 
sICAM-3, ng/ml 167 (43-674) 298 (51-1170) 0.13 
sE-selectin, ng/ml 472 (140-1098) 360 (165-1162) 0.42 
sICAM-1, ng/ml 1892 (1264-2737) 1676 (124-2839) 0.15 
sP-selectin, ng/ml 154 (59-499) 182 (21-418) 0.96 
sVCAM-1, ng/ml 3086 (719-3574) 2389 (898-3898) 0.70 
E-selectin, endothelial-selectin; ICAM-1, intercellular adhesion molecule-1; ICAM-3, 
intercellular adhesion molecule-3; PECAM-1, platelet endothelial cell adhesion 
molecule-1; P-selectin, platelet-selectin; s, soluble; VCAM-1, vascular cell adhesion 
molecule-1. 
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Table 4.  Prognostic factor for acute liver failure by univariate logistic regression 
model. 
 OR 95% CI P-value 
Age, per 1 year increase 1.02 0.97-1.07 0.45 
Gender, female 1.53 0.40-5.81 0.53 
Etiology, viral hepatitis 0.61 0.16-2.28 0.46 
Hepatic coma, III or IV 5.26 0.56-50.0 0.15 
White blood cell, per 100/mm
3 
increase 1.01 0.99-1.02 0.30 
Hemoglobin, per 1 g/dl increase 0.93 0.71-1.23 0.63 
Platelet, per 1 x 10
4
/ mm
3 
increase 0.90 0.82-0.99 0.030 
Bilirubin, per 1mg/dl increase 1.04 0.96-1.13 0.36 
D/T ratio, per 0.1 increase 0.14 0.03-0.59 0.007 
AST, per 100 IU/l increase 1.00 0.99-1.01 0.99 
ALT, per 100 IU/l increase 0.99 0.97-1.02 0.58 
Creatinine, per 1 mg/dl increase 1.95 0.68-5.60 0.22 
Prothrombin activity, per 1% increase 0.94 0.88-1.00 0.064 
sPECAM-1, per 100 ng/ml increase 1.39 1.04-1.88 0.029 
sICAM-3, per 100 ng/ml increase 1.13 0.89-1.43 0.32 
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sE-selectin, per 100 ng/ml increase 0.99 0.80-1.23 0.92 
sICAM-1, per 100 ng/ml increase 0.84 0.72-0.97 0.016 
sP-selectin, per 100 ng/ml increase 1.17 0.67-2.04 0.58 
sVCAM-1, per 100 ng/ml increase 1.01 0.94-1.08 0.75 
ALT, alanine aminotransferase; AST, aspartate aminotransaminase; CI, confidence 
interval; D/T ratio, ratio of direct to total bilirubin; OR, odds ratio; E-selectin, 
endothelial-selectin; ICAM-1, intercellular adhesion molecule-1; ICAM-3, intercellular 
adhesion molecule-3; PECAM-1, platelet endothelial cell adhesion molecule-1; 
P-selectin, platelet-selectin; s, soluble; VCAM-1, vascular cell adhesion molecule-1. 
 30 
Table 5.  Prognostic factor for acute liver failure by multivariate logistic regression 
model. 
 OR 95% CI P-value 
Platelet, per 1 x 10
4
/ mm
3 
increase 1.26 0.98-1.63 0.074 
D/T ratio, per 0.1 increase 0.11 0.01-0.99 0.049 
sPECAM-1, per 100 ng/ml increase 4.37 1.23-15.5 0.022 
sICAM-1, per 100 ng/ml increase 0.49 0.27-0.89 0.020 
ALT, alanine aminotransferase; AST, aspartate aminotransaminase; CI, confidence 
interval; D/T ratio, ratio of direct to total bilirubin; ICAM-1, intercellular adhesion 
molecule-1; PECAM-1, platelet endothelial cell adhesion molecule-1; s, soluble. 
 
 
